한글목차

세계 항정신병제 시장의 미래는 조현병, 치매, 양극성 장애, 우울증 등의 시장에서의 기회로 인해 유망합니다. 세계 항정신병제 시장은 2031년까지 약 220억 달러에 달할 것으로 예상되며, 2025년부터 2031년까지 5.8%의 CAGR을 기록할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 정신 장애의 유병률 증가와 정신건강에 대한 인식의 증가입니다.

• Lucintel의 예측에 따르면, 예측 기간 동안 치료 등급별로는 2세대가 계속해서 가장 큰 부문을 차지할 것으로 보입니다.
• 용도별로는 정신분열증 유병률의 증가로 인해 정신분열증이 가장 큰 부문을 차지할 것으로 예상됩니다.
• 지역별로는 북미가 정신건강 서비스 도입 증가와 고령화 인구의 급증으로 인해 예측 기간 동안 가장 큰 지역으로 남을 것으로 보입니다.

항정신병제 시장의 전략적 성장 기회

항정신병제 시장에는 다양한 용도에서 수많은 성장 기회가 존재합니다. 이러한 기회를 활용함으로써 이해관계자들은 서비스 제공을 강화하고 정신질환의 효과적인 치료에 대한 수요 증가에 대응할 수 있습니다.

• 새로운 항정신병제에 대한 수요 증가 새로운 항정신병제에 대한 수요는 정신질환의 유병률 증가에 따라 증가하고 있습니다. 이러한 신흥 시장 개척의 요구에 부응하기 위해 혁신적인 연구개발에 대한 수요가 증가하고 있습니다.
• 소아 정신의학에 대한 관심 : 항정신병제 치료의 소아 대상 확대는 큰 잠재력을 가지고 있습니다. 연령에 맞는 제형과 치료법을 개발함으로써 다양한 정신장애를 경험할 수 있는 이 젊은 층의 니즈를 충족시킬 수 있습니다.
• 정신과 원격 치료 서비스 : 원격 정신 의료 서비스의 확대는 정신건강 관리의 격차를 해소하는 데 도움이 되고 있습니다. 이러한 서비스는 특히 접근이 어려운 환자들의 참여도를 높이고, 실시간 화상 회선을 통해 정신과 의사와의 후속 세션을 통해 치료 순응도를 높일 수 있습니다.
• 통합 치료 모델 : 약물 치료와 다른 일반적인 환자 치료 방법을 결합한 통합 치료 모델, 특히 만성기 치료 모델을 지원하는 경향이 증가하고 있습니다. 이 접근법은 정신보건 의료 종사자와 일차 의료 시스템과의 연계를 강화하여 환자에게 더 나은 총체적 치료를 제공합니다.
• 신흥 시장으로의 세계 진출 : 신흥 시장 진출은 항정신병제 산업에 큰 성장 기회가 될 수 있습니다. 현지 요구에 맞게 제품과 마케팅 전략을 조정함으로써 치료 접근성을 개선하고 다양한 치료법의 시장을 확대할 수 있습니다.

이러한 성장 전략은 항정신병제 시장을 활성화하고, 환자의 예후를 개선하며, 필수적인 정신보건 서비스의 이용 가능성을 높일 것으로 보입니다.

항정신병제 시장 활성화 요인 및 과제

항정신병제 시장에는 기술 개선, 경제 문제, 규제 등 다양한 촉진요인과 과제가 영향을 미치고 있습니다. 이해관계자가 이러한 복잡한 직업에서 성공하려면 이러한 요인을 이해하는 것이 중요합니다.

항정신병제 시장을 이끄는 요인은 다음과 같습니다:

• 정신장애에 대한 인식의 증가 : 정신장애인의 낙인에 대한 위로에도 불구하고 정신병 치료약에 대한 수요가 있고, 항정신병제 치료 희망자도 급증하고 있습니다. 의료진과 매스미디어의 참여로 인해 사람들은 더 많은 검사를 받고 더 빠른 진단을 받기 위해 의료를 찾게 되었습니다.
• 의약품 개발 과정의 새로운 트렌드 : 지속형 주사제와 같은 약물전달 및 제형에 대한 새로운 접근 방식은 치료 순응도를 향상시키고, 그 결과 약물 사용량을 증가시키고 있습니다.
• 의료 인프라 개발 : 일부 지역에서는 의료 구조가 개선되고 더 나은 정신건강 서비스가 제공됨에 따라 항정신병제가 사용되기 시작했습니다.
• 규제 발전 : 의약품 허가 절차 간소화에 대한 규제의 발전은 항정신병제의 신약 개발을 촉진하고 업계 내 경쟁을 심화시키고 있습니다.
• 정신 질환의 증가 : 전 세계 많은 사람들 사이에서 정신 장애 사례가 증가함에 따라 정신병적 장애에 대한 강력한 치료제의 개발이 필요하며, 이는 이 시장의 성장을 촉진하고 있습니다.

항정신병제 시장의 과제는 다음과 같습니다:

• 정신건강 문제에 대한 인식 : 인식 개선에도 불구하고 정신질환에 대한 낙인이 여전히 시장 성장의 큰 장벽으로 작용하고 있습니다.
• 새로운 치료 접근법의 비용 : 정신분열증 신약 개발 및 보급에 소요되는 높은 비용은 중소기업의 장벽이 되어 시장 경쟁과 혁신을 저해하는 요인이 됩니다.
• 규제 장벽 : 신약과 바이오시밀러의 출시 과정은 복잡하고 시간이 많이 소요되는 규제 요건으로 인해 지연될 수 있으며, 제조업체와 시장 진입 기업에게 불확실성을 야기합니다.

치료 결과를 개선하고 환자들에게 더 나은 항정신병제를 제공하기 위해서는 이러한 문제를 해결하는 것이 필수적입니다. 낙인, 높은 비용, 규제 상황, 시장 포화 등의 장애물을 극복하는 것은 치료 효과를 높이고 정신건강 관리의 전반적인 상황을 개선하는 데 도움이 될 것입니다.

목차

제1장 주요 요약

제2장 세계의 항정신병제 시장 : 시장 역학

• 소개, 배경, 분류
• 공급망
• 업계 성장 촉진요인과 과제

제3장 2019년부터 2031년까지 시장 동향과 예측 분석

• 거시경제 동향(2019-2024년)과 예측(2025-2031년)
• 세계의 항정신병제 시장 동향(2019-2024년)과 예측(2025-2031년)
• 치료 클래스별 : 세계의 항정신병제 시장
  • 제1세대
  • 제2세대
• 유통 채널별 : 세계의 항정신병제 시장
  • 병원 약국
  • 소매 약국
  • 온라인 약국
• 용도별 : 세계의 항정신병제 시장
  • 정신분열증
  • 치매
  • 양극성 장애
  • 우울증
  • 기타

제4장 2019년부터 2031년까지 지역별 시장 동향과 예측 분석

• 지역별 : 세계의 항정신병제 시장
• 북미의 항정신병제 시장
• 유럽의 항정신병제 시장
• 아시아태평양의 항정신병제 시장
• 기타 지역의 항정신병제 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 업무 통합
• Porter's Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 치료 클래스별 : 세계의 항정신병제 시장 성장 기회
  • 유통 채널별 : 세계의 항정신병제 시장 성장 기회
  • 용도별 : 세계의 항정신병제 시장 성장 기회
  • 지역별 : 세계의 항정신병제 시장 성장 기회
• 세계의 항정신병제 시장 최신 동향
• 전략 분석
  • 신제품 개발
  • 세계의 항정신병제 시장 능력 확대
  • 세계의 항정신병제 시장 합병, 인수, 합작투자
  • 인증과 라이선싱

제7장 주요 기업 개요

• Alkermes
• Eli Lilly and Company
• Bristol-Myers Squibb
• Otsuka Holdings
• AbbVie
• Johnson & Johnson
• Teva Pharmaceutical Industries
• Pfizer
• Astrazeneca
• Dr. Reddy's Laboratories

영문목차

The future of the global antipsychotic drug market looks promising with opportunities in the schizophrenia, dementia, bipolar disorder, and depression markets. The global antipsychotic drug market is expected to reach an estimated $22 billion by 2031 with a CAGR of 5.8% from 2025 to 2031. The major drivers for this market are the rise in the prevalence of mental disorders and growing awareness regarding mental health.

• Lucintel forecasts that, within the therapeutic class category, second-generation will remain the larger segment over the forecast period.
• Within the application category, schizophrenia will remain the largest segment due to an increase in incidences of schizophrenic disorders.
• In terms of regions, North America will remain the largest region over the forecast period due to a rise in adoption of mental healthcare services and a surge in the aging population.

Gain Valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Antipsychotic Drug Market

The antipsychotic drug market has undergone a structural change induced by various emerging trends. These trends highlight changes in treatment habits, growing technologies, and the disease burden of patients, with the ultimate goal of making therapies more effective and improving patients' quality of life.

• Personalized Medicine: More pharmacogenomic testing to prevent relapse is being utilized when treating antipsychotics, as the era of personalized medicine has arrived. This approach aims to maximize potency and minimize observable adverse effects, ensuring better compliance and outcomes.
• Digital Health Integration: With advancements in telehealth systems and mobile applications, it has become easier to manage antipsychotic therapy. These tools allow for more active surveillance of treatment, support compliance, and provide better access to healthcare professionals for improved management.
• Long-Acting Injectable Formulations: Chronic patients with schizophrenia show better compliance with initiation and maintenance treatment due to the introduction and increased use of long-acting injectable antipsychotics (LAIs). LAIs reduce the burden of daily pill intake, which can lead to the violence associated with non-compliance, making the overall treatment more effective.
• Focus on Co-Occurring Conditions: Patients with psychotic disorders often have other comorbid conditions such as anxiety and depression. There is a growing realization that these must be addressed. The trend toward concurrent treatment of such disorders is becoming more common, contributing to overall patient care.
• Regulatory Evolution: The changing regulatory environment is flattening drug development timelines, leading to more drugs entering the antipsychotic market. This results in new drugs becoming available more rapidly, which increases competition and ultimately improves treatment options for patients.

These trends are redefining the antipsychotic drug market by providing more individualized and holistic treatment. If these trends persist, they will likely improve treatment outcomes and enhance patient satisfaction, especially for those with a complex variety of mental health disorders.

Recent Developments in the Antipsychotic Drug Market

Important developments have defined the antipsychotic drug market, enhancing treatment and patient care. Several other developments are changing the course of history, including technological advancements, regulatory changes, and evolving attitudes toward mental health.

• New Drug Approvals: There has been an increasing approval of new antipsychotic medications, along with favorable changes in their safety profiles, opening new avenues for patient treatment. New drugs are developed to treat specific symptoms and benefit patients who do not respond well to standard therapies.
• Emergence of Generic Formulations: The availability of generic antipsychotic pharmaceuticals is making it easier and more affordable for patients to receive treatment. This is especially important in low-income countries where the cost of essential drugs can be a major barrier to access.
• Advancements in Delivery Methods: The introduction of new drug administration techniques, such as long-acting injectables, is helping patients with chronic mental illness comply with treatment. These products help reduce the need for daily medication intake, minimizing relapse cases.
• Governments Working to Improve Access and Financing of Mental Health Services: Many governments are implementing policies to improve access to mental health care and resources. Such initiatives promote clearer diagnoses and approaches toward mental health disorders.
• Disease Management: There is an increase in the use of collaborative care models, where mental health care is provided alongside primary care. This integrated approach allows for both physical and mental health needs to be addressed in a single visit.

These developments are pushing the antipsychotic drug market forward, improving patient outcomes, and expanding the availability of mental health services.

Strategic Growth Opportunities for Antipsychotic Drug Market

The antipsychotic drug market presents numerous opportunities for growth across various applications. By taking advantage of these opportunities, stakeholders can enhance service provision and respond to the increasing need for effective treatments for mental health disorders.

• Increasing Need for New Antipsychotic Drugs: The demand for new antipsychotic therapeutics is driven by the rising prevalence of mental illnesses. There is a growing demand for innovative research and drug development to meet the needs of this expanding market.
• Focus on Pediatric Psychiatry: There is significant potential in expanding antipsychotic treatment to pediatric populations. Developing age-appropriate dosage forms and treatment methods will cater to the needs of this young group, who may experience a range of mental health disorders.
• Telepsychiatry Services: The expansion of telepsychiatry services is helping bridge gaps in mental health care. These services increase patient participation, particularly among hard-to-reach populations, and facilitate adherence to treatment through follow-up sessions with psychiatrists via live video link.
• Integrated Care Models: There is a growing trend toward integrated care models that combine drug treatment with other common methods of patient care, particularly in support of the chronic care model. This approach strengthens the connection between mental health workers and the primary healthcare system, providing better and more holistic care to patients.
• Global Expansion into Emerging Markets: Expanding into emerging markets presents a significant growth opportunity for the antipsychotic drug industry. Tailoring products and marketing strategies to local needs can improve access to treatment and expand the market for various therapies.

These growth strategies will push the antipsychotic drug market forward, improving patient outcomes and increasing the availability of essential mental health services.

Antipsychotic Drug Market Driver and Challenges

Various drivers and challenges impact the antipsychotic Drug market such as technological improvements, economic issues, and regulatory aspects. It is important to understand these factors if stakeholders want to succeed in such a complicated occupation.

The factors responsible for driving the antipsychotic drug market include:

• Increasing Consciousness of Mental Disorders: Despite being a consolation to the stigma attributed to mentally challenged persons, medicines for psychosis are in demand, and antipsychotic treatment seeking is also burgeoning. Staff and mass media involvement is making people seek health care more which leads to more testing and faster diagnosis.
• Emerging Trends In The Drug Development Process: New approaches to drug delivery and formulation such as long-acting injectables are resulting in better adherence to treatment and therefore growth in the use of the drug.
• Development Of Healthcare Infrastructure: There have been upgrades in the healthcare structure in several places enabling better mental health services hence the use of antipsychotic drugs.
• Regulatory Favor: Regulatory evolution concerning simplification of the drug licensing process has led to positive enhancement of the development of new antipsychotic drugs increasing competition within the industry.
• Rising Incidence Of Mental Health Disorders: The increased cases of mental disorders among many people in the world are making it necessity to develop potent medications for psychotic disorders which enhance the growth of this market.

Challenges in the antipsychotic drug market are:

• Perception of Mental Health Problems: Despite increased awareness, mental illness stigma remains a significant barrier to growth in the market.
• Cost of New Treatment Approaches: The high cost of developing and promoting new drugs for schizophrenia can be a barrier for smaller companies, hindering competition and innovation in the market.
• Regulatory Barriers: The process of bringing new drugs and biosimilars to market can be delayed due to complex and time-consuming regulatory requirements, creating uncertainty for manufacturers and market participants.

Addressing these challenges is essential for improving treatment outcomes and ensuring the availability of better antipsychotic drugs for patients. Overcoming obstacles such as stigma, high costs, regulatory hurdles, and market saturation will increase the effectiveness of treatments and enhance the overall mental health care landscape.

List of Antipsychotic Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies antipsychotic drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the antipsychotic drug companies profiled in this report include-

• Alkermes
• Eli Lilly and Company
• Bristol-Myers Squibb
• Otsuka Holdings
• AbbVie
• Johnson & Johnson
• Teva Pharmaceutical Industries
• Pfizer
• Astrazeneca
• Dr. Reddy's Laboratories

Antipsychotic Drug by Segment

The study includes a forecast for the global antipsychotic drug market by therapeutic class, distribution channel, application, and region.

Antipsychotic Drug Market by Therapeutic Class [Analysis by Value from 2019 to 2031]:

• First-generation
• Second-generation

Antipsychotic Drug Market by Distribution Channel [Analysis by Value from 2019 to 2031]:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Antipsychotic Drug Market by Application [Analysis by Value from 2019 to 2031]:

• Schizophrenia
• Dementia
• Bipolar Disorder
• Depression
• Others

Antipsychotic Drug Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Antipsychotic Drug Market

The antipsychotic drug market has seen favorable changes due to rising global awareness of mental health, advancements in drug development technologies, and a changing regulatory environment. Countries like the United States, China, Germany, India, and Japan are experiencing steady developments, including drug approvals, new treatment options, and expanded mental health services. These trends reflect a growing understanding of the importance of mental health and appropriate treatment.

• United States: In the U.S., the antipsychotic drug market has seen multiple new drug approvals, including long-acting injectable drugs that improve patient compliance. The new generation of medicines is being developed alongside functional genomics tools that help tailor antipsychotic medications to specific patients. Telepsychiatry has also gained widespread acceptance, improving access to mental health care, especially during the COVID-19 pandemic. These trends are enhancing patient outcomes by addressing primary mental health conditions and comorbid factors.
• China: The antipsychotic drug market in China has experienced rapid growth due to increased recognition of mental health issues and government emphasis on mental health programs. The market has been further supported by the emergence of generic versions of popular antipsychotic drugs, making treatment more affordable. Reforms in mental health policy and staff training are improving diagnosis and care. Additionally, technologies like digital health are assisting in patient monitoring and follow-up care.
• Germany: The antipsychotic drug market in Germany has progressed positively with the development of novel drugs and improvements in the regulatory process. These new drugs, which have better side effect profiles, are attracting interest in the market. Germany's healthcare system emphasizes evidence-based treatment protocols and psychosocial rehabilitation while increasing budget allocations and community awareness initiatives are improving societal response to antipsychotic treatments.
• India: The antipsychotic drug market in India is poised for significant growth due to the high prevalence of mental disorders and the decreasing stigma associated with mental health issues. Efforts to develop mental health care through policy initiatives and partnerships with NGOs are supporting market growth. The introduction of low-cost generics is also increasing access to antipsychotic medications. Awareness programs aimed at stigma reduction and early treatment are improving patient compliance.
• Japan: The antipsychotic market in Japan is characterized by innovation, particularly in products targeting symptoms of schizophrenia and bipolar disorder. Recent amendments to drug approval laws have expedited the availability of new treatments, improving the landscape for mental health care. The use of bipolar disorder medications, combined with cognitive behavioral therapy (CBT) and support groups, is on the rise. Furthermore, the use of telemedicine and mobile apps is helping enhance patient adherence and improve treatment efficacy.

Features of the Global Antipsychotic Drug Market

Market Size Estimates: Antipsychotic drug market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecasts (2025 to 2031) by various segments and regions.

Segmentation Analysis: Antipsychotic drug market size by therapeutic class, distribution channel, application, and region in terms of value ($B).

Regional Analysis: Antipsychotic drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different therapeutic class, distribution channels, applications, and regions for the antipsychotic drug market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the antipsychotic drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the antipsychotic drug market by therapeutic class (first-generation and second-generation), distribution channel (hospital pharmacy, retail pharmacy, and online pharmacy), application (schizophrenia, dementia, bipolar disorder, depression, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Antipsychotic Drug Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Antipsychotic Drug Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Antipsychotic Drug Market by Therapeutic Class
  • 3.3.1: First-generation
  • 3.3.2: Second-generation
• 3.4: Global Antipsychotic Drug Market by Distribution Channel
  • 3.4.1: Hospital Pharmacy
  • 3.4.2: Retail Pharmacy
  • 3.4.3: Online Pharmacy
• 3.5: Global Antipsychotic Drug Market by Application
  • 3.5.1: Schizophrenia
  • 3.5.2: Dementia
  • 3.5.3: Bipolar Disorder
  • 3.5.4: Depression
  • 3.5.5: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Antipsychotic Drug Market by Region
• 4.2: North American Antipsychotic Drug Market
  • 4.2.1: North American Market by Therapeutic Class: First-generation and Second-generation
  • 4.2.2: North American Market by Application: Schizophrenia, Dementia, Bipolar Disorder, Depression, and Others
• 4.3: European Antipsychotic Drug Market
  • 4.3.1: European Market by Therapeutic Class: First-generation and Second-generation
  • 4.3.2: European Market by Application: Schizophrenia, Dementia, Bipolar Disorder, Depression, and Others
• 4.4: APAC Antipsychotic Drug Market
  • 4.4.1: APAC Market by Therapeutic Class: First-generation and Second-generation
  • 4.4.2: APAC Market by Application: Schizophrenia, Dementia, Bipolar Disorder, Depression, and Others
• 4.5: ROW Antipsychotic Drug Market
  • 4.5.1: ROW Market by Therapeutic Class: First-generation and Second-generation
  • 4.5.2: ROW Market by Application: Schizophrenia, Dementia, Bipolar Disorder, Depression, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Antipsychotic Drug Market by Therapeutic Class
  • 6.1.2: Growth Opportunities for the Global Antipsychotic Drug Market by Distribution Channel
  • 6.1.3: Growth Opportunities for the Global Antipsychotic Drug Market by Application
  • 6.1.4: Growth Opportunities for the Global Antipsychotic Drug Market by Region
• 6.2: Emerging Trends in the Global Antipsychotic Drug Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Antipsychotic Drug Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Antipsychotic Drug Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Alkermes
• 7.2: Eli Lilly and Company
• 7.3: Bristol-Myers Squibb
• 7.4: Otsuka Holdings
• 7.5: AbbVie
• 7.6: Johnson & Johnson
• 7.7: Teva Pharmaceutical Industries
• 7.8: Pfizer
• 7.9: Astrazeneca
• 7.10: Dr. Reddy's Laboratories